Pancreatic Cancer Panel

Forms and Documents

Test Details

APC, ATM, BRCA1, BRCA2, CDK4, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53, VHL, XRCC2
  • The family history is suggestive of a predisposition to pancreatic cancer. Although the BRCA2, PALB2, CDKN2A, STK11, ATM, and Lynch syndrome genes are thought to account for a significant proportion of such cases, there are several other genes that cause an increased risk of pancreatic cancer. The OncogeneDx Pancreatic Cancer panel includes analysis of these genes as well as 6 other genes affecting pancreatic cancer risk. Thus, the OncogeneDx Pancreatic Cancer panel offers increased clinical sensitivity compared to testing only for the most commonly associated genes. Furthermore, panel testing is more cost effective than stepwise genetic testing (for example, ordering BRCA2 testing followed by additional genetic testing, if negative).
  • The differential diagnosis includes various hereditary cancer syndromes. For example, if the family history consists of multiple types of cancer, such as breast cancer in addition to pancreatic cancer, this may be associated with a cancer syndrome such as BRCA1 or BRCA2 or Peutz-Jehgers syndrome (STK11).
  • Genetic testing has already been ordered due to a family history suggestive of a hereditary cancer predisposition and all results have been negative. OncogeneDx includes genes whose role in cancer predisposition has been described recently in addition to genes associated with classic hereditary cancer syndromes.
  • Exon Array CGH
  • Next-Gen Sequencing

Ordering

B343
3 weeks
2-5 mL Blood - Lavender Top Tube
Oral Rinse (30-40 mL)

Billing

81162x1, 81201x1, 81404x1
Yes
Yes
* For price inquiries please email zebras@genedx.com

References

  1. Canto MI et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013 Mar;62(3):339-47. (PMID 23135763)
  2. Durno CA, Holter S, Sherman PM, Gallinger S. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. Am J Gastroenterol. 2010 Nov;105(11):2449-56. (PMID 20531397)
  3. Eckerle Mize D, Bishop M, Resse E, and Sluzevich J (2009). Familial Atypical Multiple Mole Melanoma Syndrome. In Riegert-Johnson DL, Boardman LA, Hefferon T, and Roberts M (Eds), Cancer Syndromes [Internet]. Bethesda (MD): NCBI.
  4. Frantzen C, Links TP, and Giles RH. Von Hippel-Lindau Disease. (2000 [updated 2012]). In Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, and Stephens K (Eds), GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle.
  5. Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterol 2010 Oct;139(4):1076-80. (PMID 20727885)
  6. Lowenfels AB and Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):197-209. (PMID 16549324)
  7. Lynch HT, Smyrk, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol. 1996 Apr;23(2):251-75. (PMID 8623061)
  8. Brand RE, Lynch HT. Hereditary pancreatic adenocarcinoma. A clinical perspective. Med Clin North Am. 2000 May;84(3):665-75. (PMID 10872423)
  9. Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. SEER Cancer Statistics Review, 1975-2009: Lifetime Risk Tables (URL: http://surveillance.cancer.gov/devcan) [July 2013 accessed].
  10. Wimmer K and Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica. 2010 May; 95(5): 699–701. (PMID 20442441)